Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for egfr and ALK testing in lung cancer in Canada

Current Oncology

Volumn 20, Issue 4, 2013, Pages 220-226

  Ionescu, D N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

AMP; Association for Molecular athology; Cap; College of American Pathologists; Guidelines; IASLC; International Association for the Study of Lung cancer; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALK GENE; CANADA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CELL COMPOSITION; CYTOLOGY; ECONOMIC ASPECT; EGFR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MATERIALS HANDLING; MUTATIONAL ANALYSIS; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PROTOCOL COMPLIANCE; QUALITY CONTROL; REVIEW; TISSUE PRESERVATION;

EID: 84881263214     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1568     Document Type: Review

References (35)

1. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011;135:110-16.
2. cap/iaslc/amp Lung Cancer Biomarkers Guideline: Draft Recommendations. Northfield, IL: College of American Pathologists; 2011. [Available online at: http://www.cap.org/apps/docs/membership/transformation/new/lung_public_comment_supporting_materials.pdf; cited June 14, 2013]
3. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
4. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
5. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
7. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of ihc and fish for ALK gene rearrangement in non-small cell lung carcinoma: ihc score algorithm for fish. J Thorac Oncol 2011;6:459-65.
8. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a ttf-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15.
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
10. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
11. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Ver. 3.2012. Fort Washington, PA: nccn; 2012.
12. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-11.
13. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-8.
14. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011;32:22-31.
15. Kamel-Reid S, Chong G, Ionescu DN, et al., EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Curr Oncol 2012;19:e67-74.
16. Bosdet I, Ali RH, Young S, Karsan A, Ionescu DN. Cytology samples are comparable to histological samples for EGFR mutation testing in non-small cell lung cancer (nsclc). Lab Invest 2012;92:474A.
17. Shiau CJ, Babwah J, da Cunha Santos G, et al. Selection of samples for epidermal growth factor receptor mutation analysis in non-squamous non-small cell lung carcinoma [abstract 2045]. Mod Pathol 2012;25(suppl 2):490A.
18. Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med 2004;128:1372-8.
19. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379-91.
20. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403.
21. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med 2011;135:622-9.
22. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med 2005;2:e73.
23. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
24. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
25. Costa DB, Halmos B, Kumar A, et al. Bim mediates egfr tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-80.
26. Sasaki H, Endo K, Takada M, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58:324-8.
27. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
28. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. [Erratum in: N Engl J Med 2011;364:588]
29. Wong DW, Leung EL, So KK, et al., on behalf of the University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33.
30. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111-16.
31. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012;106:1100-6.
32. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual ihc and fish testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348-54.
33. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of ihc and fish for ALK gene rearrangement in non-small cell lung carcinoma: ihc score algorithm for fish. J Thorac Oncol 2011;6:459-65.
34. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013;8:45-51.
35. Pirker R, Herth FJ, Kerr KM, et al., on behalf of the European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-13.